CA3006962A1 - Methods and compositions for treating migraine and conditions associated with pain - Google Patents

Methods and compositions for treating migraine and conditions associated with pain Download PDF

Info

Publication number
CA3006962A1
CA3006962A1 CA3006962A CA3006962A CA3006962A1 CA 3006962 A1 CA3006962 A1 CA 3006962A1 CA 3006962 A CA3006962 A CA 3006962A CA 3006962 A CA3006962 A CA 3006962A CA 3006962 A1 CA3006962 A1 CA 3006962A1
Authority
CA
Canada
Prior art keywords
composition
migraine
ketoprofen
pain
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3006962A
Other languages
English (en)
French (fr)
Inventor
William Bauer
Wolfgang Liedtke
Crist J. Frangakis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achelios Therapeutics Inc
Original Assignee
Achelios Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achelios Therapeutics Inc filed Critical Achelios Therapeutics Inc
Publication of CA3006962A1 publication Critical patent/CA3006962A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3006962A 2014-12-01 2015-12-01 Methods and compositions for treating migraine and conditions associated with pain Abandoned CA3006962A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462085943P 2014-12-01 2014-12-01
US62/085,943 2014-12-01
PCT/US2015/063220 WO2016089893A1 (en) 2014-12-01 2015-12-01 Methods and compositions for treating migraine and conditions associated with pain

Publications (1)

Publication Number Publication Date
CA3006962A1 true CA3006962A1 (en) 2016-06-09

Family

ID=56092337

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3006962A Abandoned CA3006962A1 (en) 2014-12-01 2015-12-01 Methods and compositions for treating migraine and conditions associated with pain

Country Status (6)

Country Link
US (3) US20170266106A1 (https=)
EP (1) EP3226972A4 (https=)
JP (2) JP2017536421A (https=)
CN (1) CN107614061A (https=)
CA (1) CA3006962A1 (https=)
WO (1) WO2016089893A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107789343A (zh) * 2017-11-08 2018-03-13 莫玉艳 一种治疗偏头痛的药物及其制备方法
CA3119728A1 (en) 2018-11-21 2020-05-28 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
JP2022521020A (ja) * 2019-02-22 2022-04-04 ペア セラピューティクス インコーポレイテッド 偏頭痛に関連付けられた症状の処置のためのシステム及び方法
CN110432888B (zh) * 2019-08-15 2021-11-23 任鹏宇 一种前庭神经权重信息编码神经元的筛选方法
US10945992B1 (en) * 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
KR20230051117A (ko) * 2020-01-10 2023-04-17 브리오리 바이오테크 인코포레이티드 로페콕시브를 함유하는 국소 조성물 및 이의 제조 및 사용 방법
EP3900715A1 (en) * 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Synergistic admixtures of gabapentin and ketoprofen, pharmaceutical compositions and their medical use
WO2022147155A1 (en) * 2020-12-31 2022-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
IL310680A (en) * 2021-08-16 2024-04-01 Cerecin Inc Methods for the treatment of migraine and related headache symptoms using tricaprylin
AU2023385700A1 (en) * 2022-11-23 2025-07-10 Medicon Pharmaceuticals, Inc. Treating pain associated with central sensitization
CN115998724B (zh) * 2023-03-28 2023-06-16 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途
WO2025111078A1 (en) * 2023-11-21 2025-05-30 Medicon Pharmaceuticals, Inc. Oral administration of compounds for treating pain

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3759980A (en) * 1969-05-26 1973-09-18 Stockton Chemicals Inc Salicylates
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
JPS60155111A (ja) * 1983-10-20 1985-08-15 Hisamitsu Pharmaceut Co Inc 安定なケトプロフェン含有外用経皮製剤
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5409704A (en) 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5032582A (en) 1987-02-27 1991-07-16 Liposome Technology, Inc. Method for treating fungal infections with amphotericin B/cholesterol sulfate composition
US4994213A (en) 1988-05-17 1991-02-19 Liposome Technology, Inc. Method of preparing lipid structures
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
US5194266A (en) 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
DE69211691T2 (de) 1991-04-19 1997-01-16 Nexstar Pharmaceuticals Inc., Boulder, Col. Pharmazeutische formulierung und pharmazeutisches verfahren
HU223343B1 (hu) 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
GR1002207B (en) 1992-08-06 1996-03-27 Johnson & Johnson Consumer Skin care compositions containing imidazoles.
US5552155A (en) 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
AU5938996A (en) 1995-06-07 1996-12-30 Nexstar Pharmaceuticals, Inc. Method for encapsulating pharmaceutical materials
US5897880A (en) 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
US6387407B1 (en) 1995-09-29 2002-05-14 L.A.M. Pharmaceutical Corporation Topical drug preparations
US5667799A (en) 1995-10-30 1997-09-16 Caldwell; Larry J. Method for treating headache pain with topical local anesthetic compositions
CN1102852C (zh) 1995-11-13 2003-03-12 皮特迈国际有限公司 含一氧化二氮的止痛药、消炎药和解热药的给药介质及含有这样的介质和药物的药物组合物
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
US5855907A (en) 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6083996A (en) 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6090368A (en) 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US6139861A (en) 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6642243B1 (en) 1999-07-22 2003-11-04 Ashkan Imanzahrai Migraine medicine and method for treating same
US6896898B1 (en) * 1999-11-19 2005-05-24 Xel Herbaceuticals, Inc. Transdermal delivery system for alkaloids of aconitum species
US20020143047A1 (en) 2001-01-05 2002-10-03 Galer Bradley S. Methods for treating indomethacin responsive headaches
US20070112052A9 (en) * 2001-01-05 2007-05-17 Larry Caldwell Methods and compositions for treating headache pain with topical NSAID compositions
DK1435945T3 (da) * 2001-06-05 2008-12-01 Ronald Aung-Din Topisk migræne terapi
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
WO2004075832A2 (en) 2003-02-27 2004-09-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
US7357950B2 (en) 2003-03-21 2008-04-15 Elizabeth Anne Mazzio Topical treatment for dyshidrosis (pompholyx) and dry skin disorders
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20050019354A1 (en) 2003-07-23 2005-01-27 Perricone Nicholas V. Topical benfotiamine treatments
CA2536096A1 (en) 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
WO2005102307A2 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US20090214466A1 (en) 2005-05-09 2009-08-27 Levin Bruce H Methods of Alleviating Disorders and Their Associated Pain
CA2620202C (en) * 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
WO2007061694A2 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin tricyclic cgrp receptor antagonists
US20090312435A1 (en) 2006-08-30 2009-12-17 Auspex Pharmaceuticals, Inc Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
US20080317684A1 (en) 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
WO2008054788A2 (en) * 2006-10-31 2008-05-08 Chrono Therapeutics, Inc. Transdermal delivery techniques for drugs, nutraceuticals and other active substances
SG10201406930UA (en) 2009-07-27 2014-11-27 Nocicepta Llc Methods For Treatment Of Pain
EP2512460A4 (en) 2009-12-18 2015-01-21 Exodos Life Sciences Ltd Partnership METHOD AND COMPOSITIONS FOR STABLE LIQUID ACTIVE FORMULATIONS
WO2011075654A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating inflammation of skin
WO2011075688A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
AU2010330813B2 (en) 2009-12-18 2016-04-28 Exodos Life Sciences Limited Partnership Methods and compositions for treating peripheral vascular disease
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
US9681837B2 (en) 2012-02-20 2017-06-20 Keio University Central sensitization diagnosis device and method for operating same
US8491917B1 (en) * 2012-03-12 2013-07-23 William J. Bender Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head
US8822537B2 (en) * 2012-09-27 2014-09-02 Achelios Therapeutics, Inc. Topical ketoprofen composition
EA030797B1 (ru) 2012-12-21 2018-09-28 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Система трансдермальной доставки гормонов (варианты) и способы ее применения
WO2017106714A1 (en) 2015-12-16 2017-06-22 Achelios Therapeutics, Inc. Methods and compositions for treating peripheral neuropathy

Also Published As

Publication number Publication date
JP2017536421A (ja) 2017-12-07
EP3226972A1 (en) 2017-10-11
US20190216720A1 (en) 2019-07-18
WO2016089893A1 (en) 2016-06-09
US20170266106A1 (en) 2017-09-21
US11026882B2 (en) 2021-06-08
US20220125712A1 (en) 2022-04-28
JP2020073563A (ja) 2020-05-14
EP3226972A4 (en) 2018-08-08
CN107614061A (zh) 2018-01-19

Similar Documents

Publication Publication Date Title
US11026882B2 (en) Methods and compositions for treating migraine and conditions associated with pain
DK2512240T3 (en) Methods and compositions for the treatment and improvement of trigeminal autonomic cephalgias, migraines and vascular conditions
US9980927B2 (en) Use of tapentadol for inhibiting and/or treating depression and anxiety
RU2667977C2 (ru) Композиции твердых растворов и их применение при сильной боли
ES2275229T3 (es) Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
EP0946155B1 (en) Pharmaceutical composition for treating fecal incontinence and anal itch
CN101340884A (zh) 用于治疗多汗症的方法
RU2701720C1 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
ES2503540T3 (es) Composición farmacéutica que combina un agente antiinflamatorio no esteroideo y un agente anticonvulsionante
CA2850964C (en) Methods and compositions for treating foot or hand pain
TW202440068A (zh) 用於治療搔癢之諾卡酮（ｎｏｏｔｋａｔｏｎｅ）
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
US9889126B2 (en) Use of naratriptan in the treatment of rosacea
WO2014049299A1 (fr) Combinaison de laropiprant et de brimonidine pour le traitement de la rosacée
WO2014049297A1 (fr) Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacée
HK1169919A (en) Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
HK1169919B (en) Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201130

FZDE Discontinued

Effective date: 20240226